ABLYNX (ABLYF) Downgraded by Zacks Investment Research to “Hold”

ABLYNX (OTCMKTS:ABLYF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Separately, Bank of America began coverage on shares of ABLYNX in a report on Friday, November 10th. They issued a “buy” rating and a $26.00 target price for the company.

ABLYNX (ABLYF) remained flat at $$24.59 during trading on Friday. ABLYNX has a 1 year low of $11.10 and a 1 year high of $50.00.

TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/ablynx-ablyf-downgraded-by-zacks-investment-research-to-hold.html.

ABLYNX Company Profile

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

Get a free copy of the Zacks research report on ABLYNX (ABLYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply